Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy

Daolu Yuwen(Nanjing Medical University), Yongqian Shu(Jiangsu Province Hospital), Minmin Fan(Nanjing University), Yuzhu Ma(Nanjing University), Jian Gao(Hebei Medical University), Yan Shen(Zhejiang Chinese Medical University), Xin Li(Heilongjiang Vocational Institute of Ecological Engineering), Qiang Xu(China Pharmaceutical University), Deqiang Wang(Jiangsu University), Wenwen Xue(Nanjing Drum Tower Hospital)
Cancer Epidemiology Biomarkers & Prevention
September 18, 2018
10.1158/1055-9965.epi-18-0569
Cited by 99

Related Papers

The significance of exosomes in the development and treatment of hepatocellular carcinoma
|Molecular Cancer|2020|509
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
|BMJ|2022|494
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
|Annals of Oncology|2019|475
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
|Journal of Clinical Oncology|2021|350